Raul Valor, MD
Pulmonary Disease · Miami, FLNPI 1982690939
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,100 of the $232,117 with a category attached, or 78.5%. 48 manufacturers reported payments, led by GSK at 45.3% of the total. Reporting peaked in 2023 at $47,130 and has fallen 70.2% since, to $14,064 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 755 payments — averaging $307.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$105K
- Boehringer Ingelheim$68K
- AstraZeneca$16K
- Sunovion Pharmaceuticals Inc.$15K
- Veran Medical Technologies, Inc.$6K
- Johnson & Johnson$5K
- plus $17K from 42 others
Across 15 payments — averaging $8137.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$70K
- Teva Pharmaceuticals USA, Inc.$23K
- AstraZeneca$16K
- Chiesi USA, Inc.$14K
What the payments were for
- Consulting fees$12,8086%
- Speaking & faculty fees$182,10078%
- Travel & lodging$14,0536%
- Food & beverage$22,74810%
- Education$2930%
- Gifts$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$65,477
- OFEV$36,422
- LONHALA MAGNAIR$14,014
- BREZTRI AEROSPHERE$8,657
- Spin$5,391
- BREZTRI$4,867
- Photofrin$4,443
- MONARCH$2,376
- GALAXY$2,246
- Monarch Platform$2,182
- SYMBICORT$1,000
- Olympus Bronchoscopes$704
- Olympus Capital Accessories$704
- Olympus Respiratory Accessories$704
- NUCALA$371
- Da Vinci Surgical System$348
- Inspire$297
- OPDIVO$247
- FASENRA$246
- ACTHAR$122
How this compares
$232,117 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 823 | $586,352 |
| OfevNintedanib Esylate | 15 | $174,154 |
| Breo ElliptaFluticasone/Vilanterol | 339 | $140,881 |
| NucalaMepolizumab | 22 | $92,404 |
| Dupixent PenDupilumab | 22 | $78,563 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $60,368 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $48,211 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $16,765 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $6,803 |
| Atrovent HfaIpratropium Bromide | 14 | $6,719 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 293 | $6,519 |
| DalirespRoflumilast | 12 | $5,101 |
| Wixela InhubFluticasone Propion/Salmeterol | 45 | $3,710 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $3,700 |
| Ventolin HfaAlbuterol Sulfate | 54 | $3,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta | $105,215 | $880,0051,307 claims |
| Boehringer IngelheimOfev | $67,815 | $174,15415 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Daliresp | $16,053 | $70,077143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.